Form 4: Bolt Biotherapeutics Exec Boosts Stake, Receives Options

Bolt Biotherapeutics' Senior VP of Finance and PAO, Sarah Nemec, acquired common stock via an ESPP and was granted 8,000 employee stock options.

Summary

• Sarah Nemec, Senior VP, Finance and PAO of Bolt Biotherapeutics, Inc. (BOLT), acquired 125 shares of common stock on December 5, 2025, at a price of $4.607 per share.
• The acquisition of common stock was made under the Issuer's Employee Stock Purchase Plan (ESPP) and is exempt under Rule 16b-3(c).
• Following this transaction, Nemec beneficially owns 1,415 shares of common stock directly.
• Nemec was granted 8,000 employee stock options on January 28, 2026, with an exercise price of $6.71 per share.
• These options will vest at a rate of 1/36th of the shares per month of continuous service following January 1, 2026.
• The employee stock options have an expiration date of January 27, 2036.
• Following the option grant, Nemec beneficially owns 8,000 employee stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management's continued commitment and alignment with shareholder interests through personal investment and long-term incentives.

Positives

• The acquisition of 125 shares of common stock by a senior executive through an Employee Stock Purchase Plan indicates a direct investment and confidence in the company's future.
• The grant of 8,000 employee stock options aligns the executive's long-term financial interests with the company's performance, incentivizing sustained growth and value creation.

Future Outlook

The employee stock options granted to the Senior VP of Finance and PAO are structured to vest monthly over 36 months, starting January 1, 2026, providing a long-term incentive tied to the company's future performance and executive retention.

Industry Context

StockSavvy.ai notes that executive stock purchases and option grants are common mechanisms to align management interests with shareholder value, particularly in the biotechnology sector where long-term development cycles are prevalent. These transactions signal management's confidence and commitment to the company's strategic direction.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of this option grant, with monthly vesting over three years, is a standard practice in the biotech industry, comparable to compensation packages seen at companies like Moderna (MRNA) or BioNTech (BNTX) for similar executive roles, aiming to retain talent and incentivize long-term performance.
• The Employee Stock Purchase Plan (ESPP) acquisition reflects a common benefit offered across many industries, allowing employees to purchase company stock at a discount, further aligning their interests with the company's success.

Corporate Governance

Related Party Transactions

• The acquisition of common stock through an Employee Stock Purchase Plan and the grant of employee stock options are transactions between an executive (Sarah Nemec) and the company (Bolt Biotherapeutics, Inc.), which are disclosed as related-party dealings under SEC regulations.

Stakeholder Impact

• Shareholders may view the insider purchase and option grant as a positive sign of management confidence and alignment with shareholder interests, potentially bolstering investor sentiment.
• Employees, particularly those participating in the ESPP and option plans, benefit from these compensation structures, which can enhance morale and retention.

Next Steps

• Continued service by the reporting person for the monthly vesting of the employee stock options, which will occur over 36 months following January 1, 2026.

Key Dates

Recommendation

The insider purchase through an ESPP and the grant of stock options to a key finance executive suggest management confidence and long-term alignment with the company's performance. While these are positive indicators, a Form 4 filing alone does not provide sufficient comprehensive financial data to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate, pending further fundamental analysis.

Keywords

Bolt Biotherapeutics, BOLT, Form 4, insider transaction, employee stock purchase plan, ESPP, stock options, executive compensation, Sarah Nemec